Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K4CD
|
||||
| Former ID |
DIB012746
|
||||
| Drug Name |
ASP-8477
|
||||
| Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 2 | [1] | ||
| Company |
Astellas Pharma Inc
|
||||
| Target and Pathway | |||||
| Target(s) | VEGF receptor | Target Info | Modulator | [1] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.